NASDAQ:DYN

Dyne Therapeutics Competitors

$16.75
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.22
Now: $16.75
$17.09
50-Day Range
$14.00
MA: $16.63
$20.23
52-Week Range
$13.50
Now: $16.75
$32.31
Volume272,925 shs
Average Volume435,082 shs
Market Capitalization$861.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Dyne Therapeutics (NASDAQ:DYN) Vs. CCXI, NKTR, PTCT, APLS, INSM, and ACAD

Should you be buying DYN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Dyne Therapeutics, including ChemoCentryx (CCXI), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Apellis Pharmaceuticals (APLS), Insmed (INSM), and ACADIA Pharmaceuticals (ACAD).

Dyne Therapeutics (NASDAQ:DYN) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 80.7% of ChemoCentryx shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 9.3% of ChemoCentryx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and ChemoCentryx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyne Therapeutics00503.00
ChemoCentryx01713.00

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. ChemoCentryx has a consensus price target of $80.7778, suggesting a potential upside of 63.48%. Given Dyne Therapeutics' higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than ChemoCentryx.

Earnings and Valuation

This table compares Dyne Therapeutics and ChemoCentryx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/AN/AN/AN/A
ChemoCentryx$36.13 million95.20$-55,490,000.00($0.98)-50.42

Dyne Therapeutics has higher earnings, but lower revenue than ChemoCentryx.

Profitability

This table compares Dyne Therapeutics and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyne TherapeuticsN/AN/AN/A
ChemoCentryx-58.10%-17.23%-11.07%

Summary

ChemoCentryx beats Dyne Therapeutics on 5 of the 9 factors compared between the two stocks.

Dyne Therapeutics (NASDAQ:DYN) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 95.3% of Nektar Therapeutics shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and Nektar Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyne Therapeutics00503.00
Nektar Therapeutics16102.00

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. Nektar Therapeutics has a consensus price target of $25.2857, suggesting a potential upside of 35.73%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than Nektar Therapeutics.

Earnings and Valuation

This table compares Dyne Therapeutics and Nektar Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/AN/AN/AN/A
Nektar Therapeutics$114.62 million29.63$-440,670,000.00($2.52)-7.39

Dyne Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics.

Profitability

This table compares Dyne Therapeutics and Nektar Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyne TherapeuticsN/AN/AN/A
Nektar Therapeutics-269.05%-30.74%-22.63%

Summary

Dyne Therapeutics beats Nektar Therapeutics on 6 of the 9 factors compared between the two stocks.

Dyne Therapeutics (NASDAQ:DYN) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 7.0% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and PTC Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyne Therapeutics00503.00
PTC Therapeutics05702.58

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. PTC Therapeutics has a consensus price target of $64.90, suggesting a potential upside of 36.34%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dyne Therapeutics is more favorable than PTC Therapeutics.

Earnings and Valuation

This table compares Dyne Therapeutics and PTC Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/AN/AN/AN/A
PTC Therapeutics$306.98 million10.90$-251,580,000.00($3.45)-13.80

Dyne Therapeutics has higher earnings, but lower revenue than PTC Therapeutics.

Profitability

This table compares Dyne Therapeutics and PTC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyne TherapeuticsN/AN/AN/A
PTC Therapeutics-123.19%-76.10%-24.60%

Summary

Dyne Therapeutics beats PTC Therapeutics on 6 of the 9 factors compared between the two stocks.

Dyne Therapeutics (NASDAQ:DYN) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Dyne Therapeutics and Apellis Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyne Therapeutics00503.00
Apellis Pharmaceuticals031012.86

Dyne Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 104.48%. Apellis Pharmaceuticals has a consensus price target of $124.6154, suggesting a potential upside of 199.84%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Dyne Therapeutics.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are held by institutional investors. 1.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Dyne Therapeutics and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyne TherapeuticsN/AN/AN/A
Apellis PharmaceuticalsN/A-336.93%-78.28%

Earnings and Valuation

This table compares Dyne Therapeutics and Apellis Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/AN/AN/AN/A
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-8.96

Summary

Apellis Pharmaceuticals beats Dyne Therapeutics on 5 of the 8 factors compared between the two stocks.

Insmed (NASDAQ:INSM) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Insmed and Dyne Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insmed00703.00
Dyne Therapeutics00503.00

Insmed presently has a consensus target price of $53.8571, suggesting a potential upside of 69.90%. Dyne Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 104.48%. Given Dyne Therapeutics' higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Insmed.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are held by institutional investors. 4.6% of Insmed shares are held by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Insmed and Dyne Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insmed-145.14%-79.58%-31.14%
Dyne TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Insmed and Dyne Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$136.47 million23.99$-254,340,000.00($3.01)-10.53
Dyne TherapeuticsN/AN/AN/AN/AN/A

Dyne Therapeutics has lower revenue, but higher earnings than Insmed.

Summary

Dyne Therapeutics beats Insmed on 5 of the 8 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and Dyne Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals012702.37
Dyne Therapeutics00503.00

ACADIA Pharmaceuticals presently has a consensus target price of $32.7647, suggesting a potential upside of 60.69%. Dyne Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 104.48%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than ACADIA Pharmaceuticals.

Insider and Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 59.4% of Dyne Therapeutics shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ACADIA Pharmaceuticals and Dyne Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Dyne TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares ACADIA Pharmaceuticals and Dyne Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million9.62$-235,260,000.00($1.60)-12.74
Dyne TherapeuticsN/AN/AN/AN/AN/A

Dyne Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals.

Summary

Dyne Therapeutics beats ACADIA Pharmaceuticals on 5 of the 9 factors compared between the two stocks.


Dyne Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41flat$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63flat$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60flat$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56flat$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70flat$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39flat$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42flat$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91flat$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49flat$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02flat$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25flat$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36flat$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84flat$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01flat$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18flat$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83flat$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68flat$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69flat$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77flat$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44flat$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77flat$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81flat$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41flat$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19flat$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29flat$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47flat$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93flat$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30flat$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75flat$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49flat$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13flat$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09flat$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99flat$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43flat$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35flat$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57flat$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58flat$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02flat$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16flat$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96flat$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05flat$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94flat$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93flat$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16flat$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57flat$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57flat$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99flat$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15flat$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26flat$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19flat$1.64 billion$428.41 million14.77
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.